Adaptimmune Therapeutics (ADAP) Prices 11.25M IPO at $17/ADS
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Adaptimmune Therapeutics (ADAP) IPO Opens Up 13%
May 6, 2015 10:45 AM EDTToday's IPO for Adaptimmune Therapeutics plc (Nasdaq: ADAP) opened for trading at $19.25 after pricing 11,250,000 American Depositary Shares (ADSs) at a price to the public of $17.00 per ADS.
BofA Merrill Lynch, Cowen and Company and Leerink Partners LLC are acting as joint book-running... More
